Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 65

Combined kidney and bone marrow transplantation for immune tolerance

Official title: Combined Kidney and Hematopoietic Stem Cell Transplantation for Tolerance Induction Between Matched Sibling Donor-recipient Pairs

Run by Rabin Medical Center · NCT05086003 · Data updated 2026-11-12

This study is testing if getting a kidney and bone marrow transplant from a matched sibling can help people stop taking immune-suppressing drugs without their body rejecting the kidney.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment20 (estimated)
SponsorRabin Medical Center
Academic / other
Locations1 site (Petah Tikva)
StatusRecruiting
StartedJanuary 19, 2016
Main results expectedDecember 31, 2025
Study endsDecember 31, 2026
Registry record updatedOctober 28, 2021
Trial IDNCT05086003 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults over 18 years old with matched sibling donors and no contraindications to the required therapies.

Probably not a fit

Patients who are pregnant, breastfeeding, or have infections such as HIV, HBV, or HCV, as well as those with a history of malignancy, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the combined transplantation of kidney and bone marrow from HLA-matched sibling donor-recipient pairs to induce immune tolerance, allowing for the potential discontinuation of immunosuppressive therapy without kidney rejection. Hematopoietic stem cells are collected from the donor weeks prior to the kidney transplant, and after the transplant, the recipient undergoes conditioning therapy followed by the infusion of the stem cell graft. The goal is to maintain mixed donor chimerism for over six months, which may enable the tapering off of immunosuppression.

Why it matters

Potential benefit: If successful, this approach could significantly reduce or eliminate the need for lifelong immunosuppressive therapy in kidney transplant recipients.

How similar studies have gone: While the approach of combining kidney and bone marrow transplantation for immune tolerance is innovative, similar studies have shown promise in the field of transplantation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age older than 18 years
* Matched siblings
* No contra-indication to thymoglobuline or total lymphoid irradiation

Exclusion Criteria:

* Pregnant women or breast feeding
* Infection with HIV, HBV or HCV
* Previous or presnt malignancy

Where it's running

  • Rabin Medical Center
    Petah Tikva, Israel
    Recruiting

Study contacts

  • Principal investigator: Moshe Yeshurun, MD — Institution of Hematology, Rabin Medical Center
  • Study coordinator: Moshe Yeshurun, MD
  • Email: moshe.yeshurun@gmail.com
  • Phone: 0526015543

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.